March 1, 1995Circulation

Shear-Induced Platelet Aggregation Is Inhibited by In Vivo Infusion of an Anti–Glycoprotein IIb/IIIa Antibody Fragment, c7E3 Fab, in Patients Undergoing Coronary Angioplasty

View Full Paper

Ask AI

Bookmark

Why the study?

Does c7E3 Fab inhibit shear-induced platelet aggregation in patients undergoing PTCA?

Structured PICO

Does c7E3 Fab inhibit shear-induced platelet aggregation in patients undergoing PTCA?

Population

6 patients undergoing percutaneous transluminal coronary angioplasty (PTCA)

Intervention

c7E3 Fab 0.25 mg/kg bolus, administered after aspirin (325 mg) and heparin (12,000 U)

Comparator

Baseline (blood collected before and after heparin treatment, prior to c7E3 Fab administration)

Outcome

Extents of ex vivo shear-induced platelet aggregation (SIPA) and antibody binding to GPIIb/IIIa measured by flow cytometrysurrogate

In vivo infusion of c7E3 Fab potently inhibits shear-induced platelet aggregation and abolishes large platelet aggregates in patients undergoing PTCA.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support GPIIb/IIIa blockade during PTCA; hypothesis-generating and requires randomized trials before any practice change.

Cite This Study

Κωνσταντόπουλος et al. (1995) studied this question.

synapsesocial.com/papers/6a8203a478e42fa194a1f8d9 https://doi.org/10.1161/01.cir.91.5.1427

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Shear-Induced Platelet Aggregation Is Inhibited by In Vivo Infusion of an Anti–Glycoprotein IIb/IIIa Antibody Fragment, c7E3 Fab, in Patients Undergoing Coronary Angioplasty

Structured PICO

Discussion

Implication

Cite This Study

Topics

Shear-Induced Platelet Aggregation Is Inhibited by In Vivo Infusion of an Anti–Glycoprotein IIb/IIIa Antibody Fragment, c7E3 Fab, in Patients Undergoing Coronary Angioplasty

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider